Valius Sciences reported that in the last 12 months, they observed several successes in solid tumors and CAR T cell therapy, including Satri-cel's approval, Ori-C101 showing 66.7% cORR at RP2D in HCC, IL9-secreting CEA CAR T reporting 57% ORR, mPFS 4.7 months across 14 patients, IM96 CAR T reporting 26.3% ORR, mPFS 3 months across doses in 19 patients, and LYL273 CAR T reporting 50% ORR, mPFS 4 months across 2 doses in 12 patients.